The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer.
Ioannis Hatzaras; Ana L Gleisner; Carlo Pulitano; Charbel Sandroussi; Kenzo Hirose; Omar Hyder; Christopher L Wolfgang; Luca Aldrighetti; Michael Crawford; Michael A Choti; et al. (Profiled Authors: Christopher Wolfgang; Kenzo Hirose; Michael Choti; Timothy Pawlik)
Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2012;14(8):532-8.
OBJECTIVES: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. METHODS: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. RESULTS: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. CONCLUSIONS: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Susan Tsai; Hugo P Marques; Mechteld C de Jong; Paulo Mira; Vasco Ribeiro; Michael A Choti; Richard D Schulick; Eduardo Barroso; Timothy M PawlikHPB : the official journal of the International Hepato Pancreato Biliary Association 2010;12(4):262-9.
Ryan T Groeschl; Ido Nachmany; Jennifer L Steel; Srinevas K Reddy; Evan S Glazer; Mechteld C de Jong; Timothy M Pawlik; David A Geller; Allan Tsung; J Wallis Marsh; et al.Journal of the American College of Surgeons 2012;214(5):769-77.
Aakash Chauhan; Michael G House; Henry A Pitt; Attila Nakeeb; Thomas J Howard; Nicholas J Zyromski; C Max Schmidt; Chad G Ball; Keith D LillemoeHPB : the official journal of the International Hepato Pancreato Biliary Association 2011;13(2):139-47.
Appears in this Publication
Author of this Publication